US Drug Patent 8,969,412: Scope, Claim Boundaries, and Competitive Patent Landscape
What does US 8,969,412 protect?
US 8,969,412 protects (i) a method and (ii) a pharmaceutical composition for intrathecal (spinal) regional anesthesia using an aqueous, preservative-free formulation of chloroprocaine HCl with defined NaCl, pH, and physiochemical parameters.
The independent claim set is narrow and formulation-driven: it requires a specific composition “consisting essentially of” specific per-mL amounts, acidified to pH 3.0 to 4.0, with no preservative, and optionally constrains osmolality and relative density.
Claims map: what is inside the protected invention?
Claim 1 (method)
Claim 1 defines the protected method as:
- Intrathecal administration to a subject in need of regional anesthesia
- Administer a composition that “consists essentially of”, per mL of solution in water for injection:
- 9-11 mg chloroprocaine HCl
- 6-8 mg NaCl
- HCl in sufficient quantity to impart pH 3.0-4.0
- water for injection
- The composition is preservative-free
Scope effect: A competitor method infringes only if it administers a materially similar formulation meeting these thresholds (subject to the “consisting essentially of” tolerance).
Claim 2 (method dependent)
Adds a physicochemical limit:
- Osmolality: 270-300 mOsm/kg
Claim 3 (method dependent)
Adds a density limit:
- Relative density at 20°C: 1.0070-1.0080
Claim 4 (composition)
Claim 4 covers the product itself:
- An aqueous solution for intrathecal regional anesthesia
- Per mL, “consisting essentially of”:
- 9-11 mg chloroprocaine HCl
- 6-8 mg NaCl
- HCl to pH 3.0-4.0
- water for injection
- Preservative-free
Claims 5 and 6 (composition dependent)
- Claim 5: osmolality 270-300 mOsm/kg
- Claim 6: relative density at 20°C 1.0070-1.0080
Scope boundaries: the “consisting essentially of” hinge
How “consisting essentially of” narrows the claims
“Consisting essentially of” generally means the formulation must include the listed components while permitting only additives or ingredients that do not materially affect the basic and novel properties of the composition.
In practice for these claims, the permitted design space is constrained by:
- Chloroprocaine HCl concentration (9-11 mg/mL)
- NaCl concentration (6-8 mg/mL)
- Acidification target (HCl to pH 3.0-4.0)
- No preservative
- Optional strictness on osmolality (270-300 mOsm/kg) and relative density (1.0070-1.0080)
Actionable boundary: If a competitor introduces ingredients that materially change pH behavior, tonicity/osmolality, or stability attributes associated with preservative-free storage, it increases non-infringement risk for staying outside “consisting essentially of.” Conversely, if they keep the formulation functionally equivalent while using trace manufacturing excipients, infringement risk depends on materiality.
Quantified claim parameters (core protected formulation)
Per-mL formulation requirements
| Parameter |
Claim requirement |
| Active |
Chloroprocaine HCl: 9-11 mg/mL |
| Tonicity agent |
NaCl: 6-8 mg/mL |
| Acid |
HCl: enough to reach pH 3.0-4.0 |
| Solvent |
Water for injection |
| Preservation |
Preservative-free |
Optional dependent-claim constraints
| Parameter |
Dependent claim limitation |
| Osmolality |
270-300 mOsm/kg (Claims 2 and 5) |
| Relative density at 20°C |
1.0070-1.0080 (Claims 3 and 6) |
Design-around and risk analysis
What does not fall inside automatically
A product or method that fails any of the following is not within the literal claim scope:
- Chloroprocaine concentration outside 9-11 mg/mL
- NaCl concentration outside 6-8 mg/mL
- pH outside 3.0-4.0
- Addition of a preservative
- Non-intrathecal route (claims are explicitly intrathecal)
Likely high-risk “at-the-margin” spaces
- pH drift around 3.0-4.0: formulation pH is typically sensitive to acid equivalents; small process differences can move tonicity and pH.
- Osmolality and density matching: if a competitor matches the dependent parameters (270-300 mOsm/kg and 1.0070-1.0080), infringement risk rises sharply if the independent claim is also met.
- “No preservative” definition: many products use antioxidants, chelators, or antimicrobial agents that might be argued as “preservatives” or otherwise as materially affecting the composition. Even without conventional parabens, the labeling and chemical intent matter.
Potential safer non-infringing approaches (conceptual)
Without relying on hypotheticals, the scope suggests the following levers:
- Adjust chloroprocaine HCl outside 9-11 mg/mL
- Adjust NaCl outside 6-8 mg/mL
- Set pH outside 3.0-4.0 (or use buffering systems not equivalent to HCl-only pH adjustment)
- Use a different route (if the program is spinal anesthesia only, this is not a practical lever)
- Use a formulation with an added preservative or ingredient that changes basic properties so it no longer “consists essentially of”
Landscape: how this claim set typically positions in chloroprocaine intrathecal prior art
Where this patent sits
These claims concentrate on a specific intrathecal chloroprocaine formulation with:
- a defined acidified pH window
- a defined NaCl range
- strict preservative-free status
- controlled osmolality and density for certain embodiments
This pattern typically appears where prior art disclosed chloroprocaine for regional anesthesia but left gaps in:
- intrathecal preservative-free stability
- precise tonicity and density targets for spinal injection tolerability
- acidified formulations that improve stability while staying compatible with intrathecal use
What matters for competitive freedom-to-operate (FTO)
The claim boundaries are formulation-centric. For FTO, the practical risk is usually:
- Other patents with overlapping chloroprocaine intrathecal formulation parameters (concentration/pH/osmolality)
- Patents covering preservative-free intrathecal anesthetic solutions broadly, where this patent may be one member of a family
- Patents covering manufacturing and packaging for preservative-free sterile solutions (even if the formulation is different, packaging/presentation claims can still block launch depending on claim coverage)
Potential infringement scenarios (practical mapping)
Scenario A: match independent claims (highest risk)
A competitor launches a preservative-free intrathecal aqueous chloroprocaine solution with:
- chloroprocaine HCl in 9-11 mg/mL
- NaCl in 6-8 mg/mL
- pH 3.0-4.0 using HCl
- water for injection
Then it likely falls within Claims 1 (method) and 4 (composition).
Scenario B: match independent claims but not dependent parameters
If osmolality or density is outside:
- 270-300 mOsm/kg or 1.0070-1.0080
Then the competitor may still infringe independent Claims 1/4 if it still meets all independent formulation limits.
Scenario C: match dependent parameters but miss independent ranges
If the product matches osmolality and density but is outside:
- chloroprocaine concentration, NaCl range, pH range, or preservative-free requirement
Then it likely avoids independent claim infringement.
Key takeaways
- US 8,969,412 protects a preservative-free intrathecal chloroprocaine HCl formulation with precise per-mL ranges: 9-11 mg/mL chloroprocaine HCl, 6-8 mg/mL NaCl, and HCl-adjusted pH 3.0-4.0, plus optional constraints on osmolality (270-300 mOsm/kg) and relative density (1.0070-1.0080).
- The claims use “consisting essentially of”, so allowable excipients are limited by whether they materially affect basic properties, with preservative-free acting as a strong exclusionary anchor.
- Competitive risk is driven by formulation equivalence, not dosing technique alone; even if the method is intrathecal, divergence must occur in one of the core numeric/pH/preservative elements or by changing formulation properties materially.
FAQs
-
Is the patent limited to a specific indication or only “regional anesthesia”?
The claims cover a “subject in need of regional anaesthesia,” without a specific disease or procedural subtype in the claim text you provided.
-
If a product is preservative-free but has pH 4.1, does it infringe?
Based on literal scope, pH 4.1 is outside the required pH 3.0-4.0 window, so it would not meet an essential claim element.
-
Do the osmolality and density limits apply to every formulation covered?
No. Osmolality (270-300 mOsm/kg) is only in dependent Claims 2 and 5, and relative density (1.0070-1.0080) is only in dependent Claims 3 and 6.
-
Can a competitor add buffering agents and still claim “consisting essentially of”?
The phrase “consisting essentially of” allows only ingredients that do not materially affect the basic and novel properties. If buffering materially changes basic properties compared with the recited HCl/pH behavior, risk increases for being outside scope.
-
Does the patent cover both the method and the drug product?
Yes. It has parallel protection: Claim 1 (method) and Claim 4 (composition), with dependent claims further narrowing product/method embodiments.
References
- United States Patent No. 8,969,412 (claims as provided in prompt).
